Business Context and Reporting Period
This Form 8-K Current Report was filed by Avalyn Pharma Inc. (Nasdaq: AVLN) on September 15, 2026. The filing reports the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Robert Meyer, M.D., to the Board of Directors as a Class II director. His term is set to expire at the annual meeting of stockholders in 2028. The Board determined that Dr. Meyer is independent under Nasdaq listing standards.
Guidance, Outlook, and Management Commentary
Management commentary highlights Dr. Meyer's extensive background in regulatory strategy, including prior roles at the FDA, Merck & Co., Inc., and Greenleaf Health Inc. The Company cites his experience advising on drug approvals and his service on other life sciences boards as key qualifications.
Compensatory Arrangements:
- Annual Retainer: $40,000.
- Initial Stock Option Grant: 31,182 shares, vesting in equal annual installments over three years.
- Annual Stock Option Grant: Eligible for 15,591 shares annually at each stockholder meeting following the effective date (first grant pro-rated).
- Exercise Price: Equal to the Fair Market Value of Common Stock on the date of grant.
The filing states there are no undisclosed arrangements regarding Dr. Meyer's selection and that he has entered into a standard indemnification agreement.
Investor Verification Checklist
- Verify the independence status of Dr. Meyer under current Nasdaq listing standards.
- Confirm the total number of outstanding stock options granted to non-employee directors under the 2026 Stock Option and Incentive Plan.
- Review the Company's most recent 10-K or 10-Q for current financial liquidity and cash runway, as this 8-K contains no financial data.
- Check for any potential conflicts of interest given Dr. Meyer's prior board service at Chimerix, Translate Bio, and Correvio Pharma.